The case for corticosteroids in the treatment of early rheumatoid arthritis
Corticosteroids are potent agents that have anti-than in the old continent. (I have no data on Asia and Africa.) Although the official views (as expressed in inflammatory effects through multiple inhibitory effects along the inflammatory pathway [1] . Hench was textbooks on both sides of the Atlantic) were similar and consistent in their universal opposition to cortico-awarded the Nobel prize for the discovery of these agents and their effect in established rheumatoid arthritis steroid treatment, surveys and trials throughout the years point to chronic corticosteroid treatment in at (RA). However, doubts over long-term efficacy and concerns over toxicity have made systemic corticosteroid least half of reported RA patients.
On what evidence is classical dogma on the position treatment in RA controversial to date. In this editorial, I will make a case for a re-examination of and more of corticosteroids in RA based? In line with most knowledge in rheumatology and other fields, it is aston-positive look on such treatment, especially in early RA, based on new paradigms and recent data.
ishing to note the paucity of published data that can stand up to critical assessment by current standards. Initial enthusiasm with corticosteroids, drugs that induced apparent cures in patients with previously From Felson et al.'s [3] review of anti-rheumatic therapy, we learn that in the early 1990s the total intractable disease, hindered the study and application of other useful drugs such as sulphasalazine and metho-number of RA patients entered in published randomized clinical trials of (slow-acting) anti-rheumatic drugs did trexate for many years. This is especially significant in view of the subsequent disillusionment with cortico-not exceed 6000. To the credit of rheumatology, the situation has been improving since then, but is still far steroids caused by the rapid appearance of unacceptable side-effects of long-term high-dose treatment, and loss removed from fields such as cardiology. Also, important data on the applicability of treatment can come from of efficacy at lower dosing.
The dogma became that treatment with systemic other sources, such as prospective cohort series and case-control studies. Although the number of patients corticosteroids caused only temporary symptomatic relief, led to habituation with the danger of ever-included in such studies is bound to be larger, it is universally recognized that bias increases as design meth-increasing doses necessary to maintain effect, and that chronic treatment universally caused unacceptable side-odology decreases. It is even more humbling to realize that the total number of controlled trials on the anti-effects. Therefore, it was to be considered a treatment of last resort, at the top of the therapeutic pyramid [2] , rheumatic efficacy of corticosteroids up to 1990 (as available to me on informal review) was very low: given mostly to patients with severe, unremitting RA or with systemic complications such as vasculitis. In accord-irrespective of the criteria applied to include studies, the total remained below 10. The total number of patients ance, corticosteroids were regarded as a category separate from the class of drugs named 'slow acting' or-in the corticosteroid arms totalled~100. In this period, the best trial was that published by the Medical Research without any substantial evidence to back the term-'disease modifying'.
Council and Nuffield Foundation in 1959 [4] . Although certainly not without flaws, this trial quite convincingly An associated idea was that RA was in most cases a benign disease, which, although incurable, caused sig-showed that corticosteroid treatment at intermediate doses (10-20 mg prednisone/day) consistently sup-nificant disability only in a minority of cases. The combination of these ideas caused most rheumatologists pressed disease activity and even slowed damage progression compared to non-steroidal treatment. However, to return to traditional treatment schemes that emphasized rest, lifestyle adjustment, treatment with non-in view of the side-effect profile in these patients and the design flaws, the results were disregarded in line steroidal anti-inflammatory drugs, and spa treatment. In unresponsive cases, i.m. gold was advised, followed with prevailing dogma. A later trial showed that stopping low-dose prednisone led to a symptomatic flare in in later decades by -penicillamine and azathioprine [2] . This treatment style (and consequent rare use of cortico-most patients [5] . A few other trials showed that highdose pulses of parenteral corticosteroids had only short-steroids) was aided in Europe by the wide availability of clinical care in general and specialized hospitals as term benefits. Despite the above scant evidence pointing the other way, the view held that oral corticosteroids well as health spas. In America and Australia, clinical care for chronic conditions such as RA quickly became led only to short-term symptomatic improvement, without lasting effect on damage progression. more and more of a problem. In the (unofficial ) view expressed by many of my colleagues who experienced
The almost universal appearance of side-effects of corticosteroid treatment at high or chronic dosing pro-this period, this is the main reason that corticosteroid use remained much more widespread in these continents vided little impetus to study corticosteroid toxicity in a There is a beneficial effect on damage progression that is already apparent at low doses: it may be case in point is corticosteroid osteoporosis: the presence of this sometimes devastating side-effect is nowhere in independent of the symptomatic effect, and additive to the effects of other disease-controlling [21] drugs. doubt. However, in an exhaustive attempt to review all prospective studies to quantify this effect, we were able Effects may continue to be apparent well after treatment is stopped [10]. to find only 18 studies and 329 patients in which bone mass was studied prospectively while on corticosteroid 3. Side-effects are limited, manageable, reversible and in one study much less than in the non-steroid control treatment for any disease [6 ] . Again, to the credit of rheumatology, the majority of studies were of rheumato-group [10]. logical origin. This scant evidence pointed to only a Apart from these results, large strides are being made limited effect of low-dose prednisone. Another example especially in the field of osteoporosis. Several agents is gastrointestinal ulceration: oft cited as an important (e.g. oestrogens, biphosphonates and vitamin D) have side-effect, but with little data to support the claim, and shown high efficacy in preventing bone loss and fractures available data pointing the other way [7] . in primary osteoporosis, and studies are now beginning Happily, this situation is changing rapidly. A parato appear that show the same effect for corticosteroid digm shift has taken place in the way we look at the osteoporosis. Although osteoporosis is but one of the disease RA and its treatment. This has provided a new many side-effects caused by corticosteroids, it has by far chance to assess the real place of corticosteroids. Several the most impact both in terms of the morbidity and long-term studies of the last two decades show that RA mortality of affected patients. The other side-effects, as seen by rheumatologists is not benign, and leads to such as hypertension, diabetes and infections, seem major disability and early death in the majority of manageable with current levels of care, and put corticopatients [8] . As anti-rheumatic treatment obviously had steroids at least in the same league of toxicity as other had limited or no effect on these long-term consequences, anti-rheumatic drugs, including non-steroidal antiincreasingly rheumatologists started to call for early and inflammatory agents. more aggressive treatment of RA [9] . This provided the In conclusion, the points I have tried to make regardimpetus for a series of high-quality trials of corticoing corticosteroid treatment in (especially early) RA steroids in early RA that have recently been completed.
are that: In this journal we have summarized the results of these trials [10-18] as part of a recent review on combination $ the 'classical' view that corticosteroid therapy protherapy [19] . Table 1 provides a brief summary. The vides only short symptomatic benefit at the price of composite message that emerges is:
unacceptable harm is not based on scientific evidence; in fact, the scant available evidence has pointed the 1. Both the magnitude and the longevity of corticosteroid effect on disease activity depend on daily other way for almost 40 yr; $ new evidence in early RA suggests that corticosteroids dose, total dose and dosing schedule. The optimum dosing schedule has yet to be found, but the sympto-are among the most potent anti-rheumatic and disease-controlling drugs available today; matic effect can be just as large as it was in the 1950s, i.e. as large or larger than that of any other anti-$ the side-effect profile of judiciously dosed cortico- 
Corticosteroids in rheumatoid arthritis-the case against
Few treatment strategies incite such diversity of opinion Compound E in RA, clinicians using corticosteroids have found these two aspects difficult to reconcile. amongst rheumatologists as the use of corticosteroids in the treatment of rheumatoid arthritis (RA).
Indeed, Hench himself, on noticing the features of iatrogenic Cushing's syndrome in some of his patients, Implicit in any decision about drug therapy is careful consideration not only of the beneficial effects of a remarked: 'Much more experience is needed before we shall know how effective or safe the prolonged use of particular agent, but also its potential toxicity. Since Hench et al.'s [1] first description of the use of Compound E will be'. Almost 50 yr later, many concerns
